Back to top

Analyst Blog

VIVUS Inc.’s (VVUS - Analyst Report) shares gained 6% after the company announced that it has inked a licensing and commercialization deal with Sanofi (SNY - Analyst Report) for its erectile dysfunction (ED) drug, Stendra (EU trade name: Spedra). However, the share price fell in the following trading sessions. Overall, the shares are up a marginal 0.4% since the announcement.

As per the terms of the deal, Sanofi will undertake the responsibility of obtaining regulatory approval and commercializing the drug in Africa, the Middle East, Turkey, and the Commonwealth of Independent States (CIS) including Russia. In exchange, VIVUS will be eligible to receive upfront payments, regulatory and sales milestone payments of up to $61 million from Sanofi. VIVUS will also receive tiered royalties on net sales of Stendra.

The Sanofi agreement marks the third deal for Stendra. Earlier, VIVUS had collaborated for the drug with privately-held Italian pharmaceutical company, Menarini (40 European countries, Australia and New Zealand) and Auxilium Pharmaceuticals, Inc. (AUXL - Analyst Report). Auxilium possesses the rights to Stendra in the U.S. and Canada.

Our Take

We are positive on the deal with Sanofi, which is in-line with the company’s strategy of finding suitable commercialization partners for Stendra.

VIVUS is also looking for a partner for its obesity drug, Qsymia, which was launched in the U.S. in Sep 2012. We are concerned about the slower-than-expected ramp up in Qsymia sales. Additionally, the competitive nature of the obesity market given the presence of Arena Pharmaceuticals, Inc.’s (ARNA - Snapshot Report) Belviq among others also keeps us concerned.

The successful commercialization of Qsymia is crucial for the financial performance of VIVUS as it can drive the company to profitability.

VIVUS, a biopharmaceutical company, currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks include Auxilium carrying a Zacks Rank #2 (Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
SUPER MICRO… SMCI 27.00 +10.25%
CANADIAN SO… CSIQ 38.34 +8.18%
CENTURY ALU… CENX 26.97 +7.97%
WILLDAN GRO… WLDN 11.38 +5.86%
AROTECH COR… ARTX 3.78 +5.59%